A detailed history of State Street Corp transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, State Street Corp holds 1,058,773 shares of TSVT stock, worth $3.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,058,773
Previous 1,043,135 1.5%
Holding current value
$3.73 Million
Previous $4.02 Million 24.43%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.85 - $5.05 $60,206 - $78,971
15,638 Added 1.5%
1,058,773 $5 Million
Q2 2024

Aug 14, 2024

BUY
$3.6 - $5.79 $153,442 - $246,787
42,623 Added 4.26%
1,043,135 $4.02 Million
Q1 2024

May 15, 2024

BUY
$3.09 - $6.0 $70,828 - $137,532
22,922 Added 2.34%
1,000,512 $5.35 Million
Q4 2023

Feb 14, 2024

SELL
$1.57 - $4.58 $143,709 - $419,230
-91,535 Reduced 8.56%
977,590 $4.17 Million
Q3 2023

Nov 14, 2023

SELL
$3.14 - $11.2 $6.25 Million - $22.3 Million
-1,991,081 Reduced 65.06%
1,069,125 $4.19 Million
Q2 2023

Aug 14, 2023

SELL
$8.45 - $12.48 $736,696 - $1.09 Million
-87,183 Reduced 2.77%
3,060,206 $31 Million
Q1 2023

May 15, 2023

BUY
$9.21 - $14.98 $7.38 Million - $12 Million
801,324 Added 34.16%
3,147,389 $32.1 Million
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $390,483 - $774,588
45,564 Added 1.98%
2,346,065 $22 Million
Q3 2022

Nov 15, 2022

SELL
$12.56 - $17.54 $2.4 Million - $3.35 Million
-191,122 Reduced 7.67%
2,300,501 $33.5 Million
Q2 2022

Aug 15, 2022

SELL
$10.55 - $18.81 $7.05 Million - $12.6 Million
-668,353 Reduced 21.15%
2,491,623 $32.9 Million
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $9.28 Million - $21.3 Million
795,625 Added 33.65%
3,159,976 $53.9 Million
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $32.6 Million - $101 Million
2,364,351 New
2,364,351 $60.6 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $133M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.